CXJ-2

N/A

Report date: 2023/03/22 16:47:50
NME

Base Information

Drug NameCXJ-2
Drug Alias NameCXJ-2
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionMitogen-activated protein kinase; ERK1/ERK2 inhibitorsPhosphatidylinositol 3 kinase alpha inhibitors
TargetsMitogen-activated protein kinase; ERK1/ERK2Phosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsLiver Cirrhosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSun Yat-Sen University
China Registration ClassN/A

Develop Information

Active CompaniesSun Yat-Sen University
Inactive CompaniesN/A
Active IndicationsLiver Cirrhosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A